KU Hematology & Medical Oncology Review 2019

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

KU Hematology & Medical Oncology Review 2019

Lung
Hematologic Malignancies
Gastrointestinal
Head and Neck
Genitourinary
Skin
Palliative
General

KU ASCO 2019 Myeloma Update: Does Subcutaneous Daratumumab Decrease the Treatment Burden of Daratumumab IV in Myeloma?

By KU Hematology & Medical Oncology Review 2019 FEATURING Al-Ola Abdallah

401 views

August 19, 2019

Comments 0

Management and Proactive Care of Adverse Events Associated with Loca…

Feat. J. Sabari, A. Spira

Insights on Proteasome Inhibitor Combinations at First Relapse in Mu…

Feat. M. Levy

Hematologic Malignancies

KU ASCO 2019 Hairy Cell Leukemia Highlights - Moxetumomab Pasudotox …

KU Hematology & Medical Oncology Review 2019

A. Yacoub

61 views

KU ASCO 2019 CML Updates - Criteria for Treatment Discontinuation & …

KU Hematology & Medical Oncology Review 2019

A. Yacoub

163 views

KU ASCO 2019 MDS & MPN Update - Luspatercept in Lower-Risk MDS & Rux…

KU Hematology & Medical Oncology Review 2019

A. Yacoub

94 views

KU ASCO 2019 Targeted Therapy Drugs for AML - CPX-351, FLT3, IDH Inh…

KU Hematology & Medical Oncology Review 2019

T. Lin

253 views

KU ASCO 2019 Update on Recent Developments in AML - CX-01, HuF59 Ant…

KU Hematology & Medical Oncology Review 2019

T. Lin

194 views

KU ASCO 2019 Myeloma Update: Lenalidomide vs Observation in Patients…

KU Hematology & Medical Oncology Review 2019

A. Abdallah

414 views

KU ASCO Review 2019: FDA Approval of Daratumumab in Combination with…

KU Hematology & Medical Oncology Review 2019

A. Abdallah

160 views

KU ASCO 2019 Myeloma Update: Efficacy of KRd With or Without Transpl…

KU Hematology & Medical Oncology Review 2019

A. Abdallah

109 views

KU ASCO 2019 Myeloma Update: Does Subcutaneous Daratumumab Decrease …

KU Hematology & Medical Oncology Review 2019

A. Abdallah

401 views

KU ASCO 2019: Update on CLL Preferred Therapy - BR vs Ibrutinib & Ib…

KU Hematology & Medical Oncology Review 2019

M. Hoffmann

386 views

KU ASCO 2019: Update on CLL Preferred Therapy - Venetoclax + Obinutu…

KU Hematology & Medical Oncology Review 2019

M. Hoffmann

945 views

KU ASCO 2019 Non Hodgkin Lymphoma Update : Polatuzumab Vedotin for R…

KU Hematology & Medical Oncology Review 2019

M. Hoffmann

462 views